BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
SOUTH SAN FRANCISCO, Calif., May 01, 2017 -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2017, and provide a general business overview on Monday, May 8, 2017 at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call Details
The live conference call on Monday, May 8, 2017, at 4:30 p.m. Eastern Time, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1-765-507-2588 internationally and using the passcode 8594347. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXaTM (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
